News|Podcasts|May 5, 2025
Novel HER2-low Therapies and Pharmacist-Led ADC Sequencing
Author(s)Alexandra Gerlach, Associate Editor
This installment of our series on ADCs and HER2 breast cancer offers key insights about novel agents in clinical trials and management of ADC therapies.
Advertisement
In this episode of the Pharmacy Times Peer Exchange feature series about antibody drug conjugates (ADCs) and human epidermal growth factor receptor 2 (HER2) breast cancer (BC), oncology pharmacists continue their discussion and move onto emerging therapies in HER2-negative and HER2-low metastatic BC. Hosted by Rose DiMarco, they also share key insights about the role of pharmacists in guiding ADC therapy sequencing.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
RSV Hospitalization Associated With Persistent Symptoms and Reduced Quality of Life in Adults
2
Study Links Specific Air Pollution Components to Increased Depression Risk in Older Adults
3
FLEX Study Data Highlight Role of Genomic Testing in Guiding Early-Stage Breast Cancer Treatment
4
December 2025 Product Updates
5